openPR Logo
Press release

Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend $40 Billion+ Market

08-19-2025 01:02 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain

The crucial role of vaccines in protecting public health couldn't have been clearer than with the recent coronavirus pandemic. COVID-19 vaccines were instrumental in helping to reduce the spread of the virus, propelling vaccines to the top ten therapy category by sales as of 2023.

At the height of the pandemic, Cominarty, which was jointly developed by Pfizer and BioNTech, emerged as the leading covid vaccine, recording peak sales of about $40 billion for two consecutive years, illustrating the commercial opportunity for vaccines.

The pandemic also sparked a new wave of innovation targeting infectious diseases, with one key breakthrough marked by the delivery of the world's first mRNA-based COVID-19 vaccine, which put a spotlight on the promise of mRNA technology.

Now, one little-known company by the name of Medicus Pharma (NASDAQ:MDCX) is set on taking mRNA technology to the next level in a move that could disrupt the global vaccine market.

Developing thermostable infectious disease vaccines

For context, Medicus Pharma is a development-stage biotech focused on commercializing a novel, non-invasive treatment for basal cell carcinoma (BCC) using a patented dissolvable microneedle array (D-MNA) patch that delivers doxorubicin directly to tumor cells. Microneedles represent a promising innovation in the field of drug delivery, offering a painless and highly efficient method to administer therapeutics.

Earlier this month, the company announced that it had entered into a non-binding memorandum of understanding with Helix Nanotechnologies Inc. to develop thermostable infectious disease vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus' proprietary MNA delivery platform.

There's a good reason why Medicus decided to jointly develop mRNA vaccines instead of traditional vaccines. mRNA vaccines teach the body to make its own antigen, resulting in faster development and stronger cell-mediated immunity. That means that vaccines can be developed in weeks instead of months or years, and since they do not use live viruses, the safety profile is significantly improved.

But unlike conventional mRNAs, HelixNano uses engineered, ultra-compact mRNA constructs designed to be more potent, stable, and efficiently deliverable in formats like microneedle patches. That means its vaccines or therapies may end up requiring smaller doses for the same immune response, reducing production cost and easing delivery. Moreover, this mRNA technology offers the potential for greater thermostability, addressing the cold chain burden seen with Pfizer or Moderna vaccines.

"The potential of combining HelixNano's potent mRNA vaccine platform with our uniquely formulated dissolvable microneedle array (MNA) technology is designed to unlock the next generation vaccination paradigm," stated Dr. Raza Bokhari, Executive Chairman & CEO, "aiming to develop needle-free, thermostable vaccines that could eliminate cold-chain logistics, reduce distribution costs, improve patient access, and offer global scale, which could potentially position us at the forefront of groundbreaking opportunities to prevent, rather than treat, infectious diseases."

Multibillion-dollar opportunity for solving vaccine cold-chain logistics

The successful development of thermostable mRNA vaccines has the potential to disrupt the broader vaccine industry which according to recent reports will be worth at least $78 billion by 2029.

"Current mRNA vaccines, such as those from Pfizer-BioNTech and Moderna, require cold storage at temperatures ranging from -20 degrees C to -70 degrees C, adding an estimated up to $7 in logistics costs per dose due to specialized freezers, insulated shipping containers, backup power systems, and temperature monitoring. These cold chain requirements significantly increase distribution costs and complexity, particularly in low-resource or remote settings, where infrastructure is limited or non-existent. In large-scale campaigns, this translates into billions of dollars in added cost and logistical risk, with even minor temperature deviations potentially leading to full batch losses," explains Dr. Raza.

A microneedle patch that allows for room temperature stable mRNA delivery could therefore eliminate most of these cold chain expenses, streamline global distribution, and unlock entirely new markets representing a major cost-saving advantage for both drug developers and public health systems.

MNA patches could revolutionize the global vaccine market by removing the need for syringes, cold storage, and trained healthcare workers. In addition to that, these patches are well suited for scalable manufacturing since they are compatible with mass production, have long shelf life, and support large-volume rollout, making them ideal for national stockpiles and COVAX type efforts.

Essentially, the joint technology by Medicus and HelixNano would directly support global pandemic readiness by offering a scalable, storable, and deployable platform for future outbreaks and endemic disease control.

So far, HelixNano has already completed 18 month stability testing on its clinical grade mRNA batch and teams are reviewing formulation compatibility with the microneedle patch. According to Dr. Raza, initial feedback from the patch manufacturer is technically promising. The development of a clinical-grade vaccine batch is already in progress, putting the new platform on a path toward human trials and regulatory milestones in the near term.

The great thing about this new technology platform is that it won't be limited to covid-type vaccines. Although its initial focus will be on infectious diseases, the platform is agnostic to the payload, enabling future expansion into other therapeutic areas such as cancer vaccines, autoimmune disorders, and more.

What's more is that since Medicus owns the proprietary MNA delivery system, it has strong IP leverage in vaccine partnerships and licensing opportunities beyond the joint venture with HelixNano.

Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Medicus Pharma to assist in the production and distribution of content related to MDCX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=medicus-pharma-nasdaqmdcx-solution-to-vaccine-cold-chain-storage-could-upend-40-billion-market]
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Medicus Pharma (NASDAQ:MDCX) Solution To Vaccine Cold Chain Storage Could Upend $40 Billion+ Market here

News-ID: 4149877 • Views:

More Releases from ABNewswire

Granny Kelly's 'A Star for Christmas Eve' Book and Freddie Star Plush Toy Launch Pre-Orders, Creating a New Holiday Tradition for Families
Granny Kelly's 'A Star for Christmas Eve' Book and Freddie Star Plush Toy Launch …
This heartwarming children's book and companion toy set address children's quiet Christmas anxieties, pairing a soothing story with a tangible keepsake to deliver comfort and joy, available just in time for the 2025 holiday season. Christmas magic arrives early this year as pre-orders open for A Star for Christmas Eve, a new children's book by Granny Kelly that pairs the warmth of holiday storytelling with a soft toy Freddie Star children
RHINO MUD Men's Skincare Highlights Superior Concentration for Black Friday as Shoppers Question Paying Premium Prices for Water-Based Products
RHINO MUD Men's Skincare Highlights Superior Concentration for Black Friday as S …
Austin Brand's 17-Botanical Formula Offers Alternative to Diluted Competitors as Holiday Shopping Season Approaches AUSTIN, TX - With Black Friday approaching, RHINO MUD Men's All-Natural Skincare is positioning its concentrated, waterless formula as a premium alternative for holiday shoppers seeking meaningful skincare gifts. While most skincare products contain harmful synthetics and are up to 75% water, the Austin-based brand's Face Serum features 17 active botanical extracts in an alcohol-free, fast-absorbing waterless
Bristol-Based F.H.C. Construction LLC Strengthens Position as Leading General Contractors in Bristol Area
Bristol-Based F.H.C. Construction LLC Strengthens Position as Leading General Co …
F.H.C. Construction LLC, Bristol's established remodeling contractor with 17+ years of experience, serves Bucks County, Philadelphia, and Southern NJ with comprehensive renovation services backed by premium materials and warranties. F.H.C. Construction LLC, [https://fhcconstructionllc.com/] a Bristol-based remodeling company with over 17 years of industry experience, continues to meet growing demand for residential renovation services across Bucks County, Philadelphia, and Southern New Jersey. Founded in 2010 by Frank Hernandez, the company has built
Hickory Homeowners Gain Access to Scientifically Proven Roof Restoration Technology
Hickory Homeowners Gain Access to Scientifically Proven Roof Restoration Technol …
Roof Maxx of Hickory, NC, brings scientifically proven shingle treatment to western North Carolina, offering homeowners a cost-effective way to extend roof life up to 15 years while avoiding expensive replacements. Homeowners in Hickory and surrounding North Carolina communities now have access to a scientifically validated treatment that extends the life of aging asphalt roofs by up to 15 years. Roof Maxx of Hickory, NC has made this roof restoration [https://maps.app.goo.gl/HbwHH8z8rCduu7w36]

All 5 Releases


More Releases for Medicus

Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology
Skin cancer is rarely viewed as life-changing, but for millions of patients each year, basal cell carcinoma brings a cycle of surgeries, scars, and slow recovery that feels endless. Hospitals are overloaded, dermatologists are booked months in advance, and treatments that remove tumors often leave lasting damage. The challenge is not identifying the cancer; it is finding a way to treat it without cutting the patient open. That is the
Medicus Pharma (Nasdaq: MDCX) Bringing Scar-Free, Outpatient Treatment to an $8 …
Every year, millions of patients face cancer treatments that leave more scars than solutions. Basal cell carcinoma, prostate cancer, and acute urinary retention each carry not only physical burdens but staggering financial and emotional costs. Hospitals are overextended. Insurers are under pressure. Patients endure painful procedures, slow recoveries, and therapies that often fail to improve outcomes. The problem is not a lack of ambition in oncology. The problem is proof. Medicus
Medicus Pharma Ltd. (NASDAQ: MDCX) Builds Momentum With Antev Acquisition and Pi …
In the biotech sector, meaningful news often serves as the spark that brings smaller companies into sharper investor focus. Clinical readouts, regulatory decisions, and strategic acquisitions can materially shift the outlook for a business that may have otherwise flown under the radar. These developments not only shape the future of a company's pipeline but can also reframe its value proposition in the eyes of the market. For investors, recognizing when
Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Coul …
Skin cancer is the most common form of cancer in the United States, with more than 9,500 cases getting diagnosed every day. In fact, more people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. The most common form of skin cancer is basal cell carcinoma (BCC), which accounts for over 5 million cases of all skin cancers diagnosed in the U.S. each year. Currently,
Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotec …
The global population is aging rapidly, with the number of people aged 65 and older expected to double by 2050. This demographic shift is driving a surge in chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. At the same time, breakthroughs in biomedical research are enabling the development of targeted, more effective therapies, transforming treatment approaches in both human and veterinary medicine. These twin forces, rising demand fueled by
Pediatric Tourniquet Market Scope By Players - Safeguard Medical, DarMar, Medicu …
MarketsandResearch.biz has newly added a research report titled Pediatric Tourniquet Market 2023 is a detailed and dedicated analysis of the present scenario of the market covering the various aspects applicable to business growth. The report evaluates the market, putting forth all-inclusive data that enriches the scope, understanding, and application of this report. The report encompasses the information on the global Pediatric Tourniquet market's status. It presents a detailed analysis of